Risk factors for cardiotoxic adverse reactions in the treatment of tuberculosis patients with MDR and XDR of the pathogen
Open Access
- 13 August 2023
- journal article
- Published by In-Trend in Tuberculosis and socially significant diseases
- Vol. 11 (3) , 39-48
Abstract
Modern treatment regimens for tuberculosis with multiple and broad drug resistance (MDR/XDR) of the pathogen provide for the simultaneous administration of several drugs with a proven cardiotoxic effect in the form of prolongation of the QTc interval and provocation of life-threatening arrhythmias. In conditions of the spread of cardiovascular and other comorbid pathology, it is important to assess the risk of cardiotoxic reactions and ensure the safety of patients during the entire course of treatment. The aim of the study was to assess the degree and risk of prolongation of the QTc interval in tuberculosis patients with MDR/XDR pathogen, including concomitant cardiological pathology, against the background of treatment regimens with the inclusion of bedaquiline.Materials and methods of research. The retrospective study included 185 tuberculosis patients with MDR/XDR of the causative agent: 70 people with cardiovascular pathology (except decompensation of heart failure, bradyarrhythmias, ventricular arrhythmias and QTc prolongation in the anamnesis) and 115 people. without it, who received chemotherapy with the inclusion of bedaquiline and fluoroquinolones. The dynamics of clinical symptoms and ECG were evaluated against the background of treatment. Risk factors for cardiotoxic reactions were determined using the method of multiple logistic regression.The results of the study. Prolongation of the QTc interval was observed in 58 people (31.4%, 95% CI 25.1–38.4%), clinically significant (more than 500 ms, 60 ms or more from the baseline, with ventricular arrhythmia) – 4.3%; bradycardia – 3.8%, cardialgic syndrome – 8.1%. Risk factors for prolongation of the QTc interval were the presence of any cardiovascular disease (OR 2.33, 95% CI 1.23-4.41), simultaneous administration of three or more drugs that can lead to QTc prolongation (OR = 3.31, 95% CI 1.73–6.32), clarithromycin administration (OR = 4.01, 95%CI 1.4710.97), the number of points on the Tisdale scale is more than 6 (OR = 3.42, 95% CI 1.78–6.62).Conclusion. Prolongation of the QTc interval is a common adverse reaction in the treatment of tuberculosis with MDR /XDR pathogen, clinically significant in 4.3% of cases. The use of a standard ECG monitoring scheme is justified; it is necessary to avoid prescribing three or more drugs that affect the QTc interval to patients with any cardiovascular pathology with a Tisdale score of more than 6 points.Keywords
This publication has 13 references indexed in Scilit:
- QT Interval Prolongation in People Treated With Bedaquiline for Drug-Resistant Tuberculosis Under Programmatic Conditions: A Retrospective Cohort StudyOpen Forum Infectious Diseases, 2021
- Effectiveness and Cardiac Safety of Bedaquiline-Based Therapy for Drug-Resistant Tuberculosis: A Prospective Cohort StudyClinical Infectious Diseases, 2021
- QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trialThe Lancet Infectious Diseases, 2021
- Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trialThe Lancet Respiratory Medicine, 2019
- EFFICACY AND SAFETY OF CHEMOTHERAPY REGIMENS WITH BEDAQUILINE IN PATIENTS WITH RESPIRATORY TUBERCULOSIS: IMMEDIATE AND FINAL RESULTSTuberculosis and Lung Diseases, 2019
- EXPERIENCE OF TREATMENT OF MULTIPLE DRUG RESISTANT TUBERCULOSIS PATIENTS WITH BEDAQUILINE IN AMUR REGIONTuberculosis and Lung Diseases, 2018
- QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: a Tuberculosis Network European Trialsgroup (TBnet) studyEuropean Respiratory Journal, 2018
- Cardiac safety of bedaquiline: a systematic and critical analysis of the evidenceEuropean Respiratory Journal, 2017
- Development and Validation of a Risk Score to Predict QT Interval Prolongation in Hospitalized PatientsCirculation: Cardiovascular Quality and Outcomes, 2013
- Drug-Induced Long QT SyndromePharmacological Reviews, 2010